Lookup NU author(s): Dr Vijay Kunadian
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Methods: The present cohort is a subset of 1657 PCI patients (pts) with evaluable angiographic data from the 18,624 pts PLATO trial. Clopidogrel naïve or pre-treated pts were randomized to 180mg ticagrelor or 300mg clopidogrel. PCI pts were administered, as per treatment group, additional 90mg ticagrelor if >24hrs after the initial loading dose or an optional further 300mg clopidogrel or placebo (total 600 mg) prior to PCI. The substudy primary endpoint was the incidence of post PCI TIMI myocardial perfusion grade 3 (TMPG 3) among patients who received the drug prior to PCI. Pre-PCI TMPG, Corrected TIMI frame count (CTFC), TIMI thrombus grade (TTG), TIMI flow grade (TFG), minimum lumen diameter (MLD) and % diameter stenosis (DS) were also measured. Results: TMPG 3 post PCI was similar between the ticagrelor and clopidogrel groups [Table]. Likewise there was no difference in CTFC (median 78 vs. 62), TMPG 3 (32.6 vs. 32.5%), TFG 3 (39.9 vs. 40.9%), TTG 0 (26.3 vs. 29.3%), and MLD (Q1-Q3) [0.3 (0.0-0.6) vs. 0.3 (0.0-0.6) mm] and %DS of culprit artery [88 (76-100) vs. 88 (76-100)%] prior to PCI between the 2 groups respectively. Conclusion: In the PLATO angiographic sub-study, the angiographic outcomes including TMPG were similar among patients treated with ticagrelor and clopidogrel.
Author(s): Kunadian V, Zorkun C, James S, Wu J, Muhammad A, Storey R, Steg G, Katus H, Emanuelsson H, Horrow J, Maya J, Wallentin L, Harrington R, Gibson CM
Publication type: Conference Proceedings (inc. Abstract)
Publication status: Published
Conference Name: American College of Cardiology: American College of Cardiology i2 summit
Year of Conference: 2011
Publisher: Elsevier Inc.
Library holdings: Search Newcastle University Library for this item
Series Title: Journal of the American College of Cardiology